Investing

Cerus : CERS

CERS

Stock Data

$2.62

$0.09 (3.56%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

MEDICAL DEVICES

Cerus Corp is a biomedical company dedicated to improving blood safety. It specializes in the INTERCEPT Blood System, a technology aimed at reducing pathogens in blood components for transfusion. This system is applied to platelets, plasma, and red blood cells, aiming to make blood transfusions safer by inactivating blood-borne pathogens. Additionally, it offers a solution for producing pathogen-reduced fibrinogen complex, crucial for treating bleeding disorders. Cerus markets its products globally, serving healthcare providers in the U.S., Europe, and beyond, with a focus on enhancing transfusion safety and patient care.

All Cerus Articles

5 Articles

Lee Jackson | Aug 26, 2023 at 6:15 AM EDT

5 Stocks Wall Street and ARK’s Cathie Wood Love Are Trading Under $10 With Huge Upside Potential

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential.…

Lee Jackson | Aug 12, 2023 at 6:15 AM EDT

Cathie Wood’s ARK Funds Are Loading Up on These 5 Red-Hot Stocks Trading Under $10

These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look…

Lee Jackson | Jul 29, 2023 at 6:10 AM EDT

Cathie Wood’s ARK Funds Include 5 ‘Strong Buy’ Stocks Under $10 With Huge Upside Potential

These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look…

Lee Jackson | Jul 15, 2023 at 6:04 AM EDT

5 Stocks Under $10 With Massive Upside Potential and ARK’s Cathie Wood Loves Two of Them

Here's a look at smaller cap companies that could very well offer patient investors some huge returns for the rest…

Chris Lange | Jul 12, 2021 at 8:05 AM EDT

Jim Cramer’s Game Plan for This Week and the Start of Earnings Season

24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.